{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Questions should be directed to the child, but the caregiver/adult should be encouraged to add relevant information.', 'It should be noted that the CDI-2 has individual parent and child questionnaires.', 'Patients who complete the study may be eligible to begin participation in an open-label safety extension study', 'TV50717-CNS-30047 after the end of the washout period. At the week 13 visit, patients may choose to enter', 'Study TV50717-CNS-30047 (on that day), or they will have an additional week to make a decision and return for', 'day 1. Patients not participating in Study TV50717-CNS-30047 will have a follow-up telephone contact to evaluate', 'safety 1 week after the end of the washout period (2 weeks after their last dose of IMP).', \"Screening period (up to 31 days): After informed consent/assent, depending on the child's age, as appropriate, is\", 'obtained, patients who are stable from a medical and psychiatric standpoint will undergo a screening evaluation,', 'including medical history, physical and neurological examination, laboratory testing, and 12-lead ECG, along with', 'rating scales to assess severity, frequency, and impairment of ties and comorbid TS symptoms and behavioral status.', 'At the discretion of the investigator, the screening visit may be divided into 2 visits if the visit length is felt to be too', 'burdensome for the patient. If the screening visit is divided into 2 visits, the blood sample should be obtained during', 'the first of the 2 visits. Patients who have received comprehensive behavioral intervention for tics (CBIT) for TS or', 'cognitive behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) may participate in this study as long', 'as therapy was completed at least 4 weeks prior to screening. Patients will return to the clinic on day 1 for baseline', 'procedures and to re-confirm eligibility. Patients may be rescreened 1 time if there is a change in the status of the', 'patient regarding eligibility for the study. (Note: Details of rescreening must be approved and documented by the', 'medical monitor and/or Clinical Surveillance and Training [CST] team.)', 'YGTSS Rater Certification: All investigators and subinvestigators who will be administering the YGTSS from', 'screening through the end of study visit must undergo and pass a Rater Certification Program which will be', 'provided separately from this protocol. Every effort must be made to ensure that the same certified rater administers', 'the YGTSS to a specific patient at all visits, especially at the baseline and week 12/early termination visits.', 'However, if due to unforeseen circumstances the same rater is absolutely unavailable to complete a visit rating, the', 'YGTSS can be administered only by another certified individual from that study site.', 'Titration period (7 weeks): Patients who remain eligible for participation in the study will be randomized at the', 'baseline visit (day 1), and that evening (ie, after the study visit) will receive 6 mg of blinded IMP with food. Tablets', 'should be taken with food (eg, a snack) and should not be taken on an empty stomach. The titration scheme and', 'maximum dose will be determined by body weight and CYP2D6 impairment status at baseline, as shown in the', 'tables below. Patients and their caregiver/adult will interact weekly with the clinical research staff, either by', 'telephone contact or clinic visit from week 1 through week 7 of the titration period, in order to evaluate safety and', 'establish a dose of IMP that optimally reduces tics and is well tolerated (optimal dose). Safety evaluations during', 'titration include assessment of vital signs, monitoring for adverse events and concomitant medications, 12-lead', 'ECGs, and rating scales for depression and suicidality.', 'In-person (in-clinic) study visits will be scheduled at weeks 2, 4, and 6, and telephone contacts will be scheduled for', 'weeks 1, 3, 5, and 7 in order to assess tic severity and adverse events. The dose of the IMP should be increased on a', 'weekly basis until one of the following criteria is met:', 'The investigator determines there has been a clinically meaningful reduction in tics as indicated by', 'a', 'sustained reduction in the TS-CGI.', 'The patient experiences a protocol-defined \"clinically significant\" adverse event (defined as an adverse', 'event that is related to study medication and is either moderate or severe in intensity or meets the', 'criteria for a serious adverse event).', \"The maximum allowable dose is reached based on the patient's weight and CYP2D6 impairment status\", 'at baseline.', '12']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Although dose adjustments can be made up to and including the week 7 telephone call, if a stable dose is reached', 'before then, the patient should continue on that dose (ie, the dose should not be increased further) for the remainder', 'of the titration period and throughout maintenance dosing, unless there is a change in symptoms during the titration', 'period. If a patient experiences a \"clinically significant\" adverse event attributable to the IMP, the investigator will', 'determine if a dose reduction or suspension is necessary. If the determination that a patient requires a dose reduction', 'or suspension is made during a telephone contact, an unscheduled clinic visit should be conducted as soon as', 'practicable thereafter.', 'Dose adjustments should be made based on all available information, including the patient and caregiver/adult', 'reports of adverse events and tic reduction, the clinical assessment of safety and efficacy by the investigator, and', \"information from rating scales. At the end of the titration period, the patient's dose will be established for the\", 'maintenance period.', 'Maintenance period (5 weeks): Patients will continue to receive their maintenance dose over the next 5 weeks,', 'although dose reductions for adverse events are allowed. Patients will return to the clinic at weeks 9 and 12 for', 'assessments of safety and efficacy. At week 12, patients will undergo a complete evaluation, including physical and', 'neurological examination, safety laboratory testing, and 12-lead ECG, CDI-2, and C-SSRS assessments, as well as', 'the YGTSS, TS-CGI, TS-PGII,', 'and C&A-GTS-QOL. In addition, patients', 'will undergo pharmacokinetic sampling at week 12.', 'Washout period and follow-up: All patients will discontinue IMP at the week 12 visit and will return 1 week later', 'for evaluation of safety and tic reduction (week 13). Patients who complete the study may be eligible to begin', 'participation in the open-label safety extension study, TV50717-CNS-30047, at that time. For this study, the', 'follow-up period is defined as 1 week of washout for patients who will participate in the open-label safety extension', 'study TV50717-CNS-30047 and 2 weeks after the last dose of IMP (1 week after the end of the washout period) for', 'patients who will not roll over into the open-label safety extension study TV50717-CNS-30047. At the week 13', 'visit, patients may choose to enter Study TV50717-CNS-30047 (on that day), or they will have an additional week', 'to make a decision and return for day 1. Patients not participating in Study TV50717-CNS-30047 will have a', 'follow-up telephone contact for safety evaluation 1 week after the end of the washout period (2 weeks after their last', 'dose of IMP [week 14]).', 'Prohibited drugs will remain the same during the washout period for patients who will participate in the open-label', 'extension study TV50717-CNS-30047', 'Patients who will not participate in the extension study (Study TV50717-CNS-30047) may begin/resume tic therapy', 'medication after the first week of the washout period.', 'Method of Blinding and Randomization:', 'Patients will be randomly assigned to receive treatment with TEV-50717 or matching placebo in a 1:1 ratio using an', 'IRT. Patients will be stratified by age at baseline (6 to 11 years, 12 to 16 years). Patients and investigators will', \"remain blinded to treatment assignment during the study. In addition, the sponsor's clinical personnel and all\", 'vendors (with the exception of the IRT vendor and the bioanalytical sample analysis vendor) involved in the study', 'will be blinded to the IMP identity until the database has been locked for analysis and the treatment assignments are', 'revealed. After unblinding of this study, the study site may remain blinded to patient treatment assignments until', 'completion of the safety extension study TV50717-CNS-30047.', 'IMP Dose, Mode of Administration, and Administration Rate:', 'IMP will be administered as oral tablets at a starting dose of 6 mg. Titration schemes based on body weight at', 'baseline are shown in the tables below. The maximum daily dose is determined by body weight and CYP2D6', 'impairment status at baseline (see the table below). Although dose adjustments can be made up to and including the', '13']\n\n###\n\n", "completion": "END"}